EDITION OF WED 11 NOV 2026
36 · BUSINESS

FDA orders vision-loss risk warning for GLP-1 drugs

publishers 48articles 50first reported 9 Nov, 16:45 UTCdeveloping since 9 Nov · 7 editions

The U.S. Food and Drug Administration has directed manufacturers of GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, to add warnings about a potential increased risk of a rare eye condition that can cause permanent vision loss.

The condition, non-arteritic anterior ischemic optic neuropathy, or NAION, occurs when blood flow to the optic nerve is reduced. It can cause sudden, painless loss of vision, usually in one eye. The FDA advised health care providers to consider discontinuing GLP-1 treatment when symptoms develop unless the benefits clearly outweigh the risk. People who have previously had NAION face an increased risk, the agency said.

The FDA said its decision followed a review of clinical trials, observational research and other evidence, including a 2024 study that prompted further investigation. An analysis of 126 randomized controlled trials found 6.4 NAION cases per 100,000 person-years among patients receiving GLP-1 drugs, compared with 3.8 cases among those given a placebo or a non-GLP-1 glucose-lowering treatment.

The evidence indicates a possible association but does not establish that the medications cause NAION. Novo Nordisk, which makes Ozempic and Wegovy, said available research has not demonstrated a causal relationship. The FDA nevertheless ordered manufacturers to include the potential risk in the warnings and precautions sections of the drugs’ labels.

HOW THIS STORY WAS MADE

Written from 8 articles, 2 with the publisher's own text; 8 independent newsrooms once syndicated copies count as one; this version written 42 h after the record first saw the story; the editor kept it as written.

Publishers
48
Source articles
50
Given to the writer
8, 2 with the article's own text
Independent newsrooms
8
This version written
42 h after the record first saw the story
Second model (editor)
kept as written
Publication gate
passed
Human review
none

WHAT THE EDITOR DID

The second model checked the writer's draft against the same sources and published it as written.

Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →

NAMED IN THE COVERAGE

OUTLETS CARRYING THE STORY, RUN BY RUN

0 25 51 10 Nov 11 Nov 12 Nov 13 Nov 14 Nov 15 Nov 10 Nov 00:19 UTC · US FDA orders new eye risk warnings for Ozempic, Zepbound 10 Nov 06:14 UTC · US FDA orders new eye risk warnings for Ozempic, Zepbound 10 Nov 18:17 UTC · US FDA orders new eye risk warnings for Ozempic, Zepbound 11 Nov 00:15 UTC · US FDA orders new eye risk warnings for Ozempic, Zepbound 11 Nov 12:16 UTC · FDA orders vision-loss risk warning for GLP-1 drugs 12 Nov 18:29 UTC · FDA orders vision-loss risk warnings for GLP-1 drugs

WHAT HELD, WHAT CAME LATER

From the first reports to the latest

  • Novo Nordisk · 3 outlets
  • Eli Lilly · 2 outlets

Entered the story later

  • 126 clinical trials · from 11 Nov 08:45, 2 outlets
  • 100,000 person-years among · from 11 Nov 08:45, 2 outlets
  • 100,000 people followed · from 11 Nov 08:45, 2 outlets

Figures reported with different numbers

  • people followed: 100,000 (2 from 11 Nov 08:45) → 50,000 (1 from 11 Nov 08:45)

Matched by pattern, not read: a different number can be a correction, a rising count, or two different counts.

HOW THIS STORY DEVELOPED: EVERY HEADLINE, EVERY OUTLET →